MedTrace Logo

Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Cindilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer

NCT05312840 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-04-06

No results posted yet for this study

Summary

To observe the efficacy and safety of conventional and low-dose platinum Gemcitabine combined with Cindilimab with delayed administration in first-line treatment of advanced squamous non-small cell lung cancer.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Cisplatin / Carboplatin，Gemcitabine，Cindilimab

1\. Routine dose group: Every three weeks as a cycle. On the first day of each cycle, Gemcitabine 1000mg / m2, Cisplatin 75mg / m2 / Carboplatin auc5 were injected intravenously, and Gemcitabine 1000mg / m2 and Cindilimab 200mg were injected intravenously on the eighth day; 2. Low dose group: every three weeks as a cycle. On the first day of each cycle, Gemcitabine 750mg / m2, Cisplatin 56mg / m2 / Carboplatin auc3 were injected intravenously 75. On the eighth day, Gemcitabine 750mg / m2 and Cindilimab 200mg were injected intravenously.

Sponsors & Collaborators

  • People's Hospital of Quzhou

    lead OTHER

Principal Investigators

  • Xuru Jin · People's Hospital of Quzhou

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05312840 on ClinicalTrials.gov